A Phase 1 Study to Evaluate the Safety and Tolerability of Subcutaneous Injection of STP705 in Adult Subjects Undergoing Abdominoplasty
Latest Information Update: 20 Mar 2024
At a glance
- Drugs STP 705 (Primary)
- Indications Skin disorders
- Focus Adverse reactions; Proof of concept
- Sponsors Sirnaomics
Most Recent Events
- 15 Mar 2024 Status changed from active, no longer recruiting to completed.
- 05 Feb 2024 According to a Sirnaomics media release, company presented latest developments and positive data from phase I study of STP705 for focal fat reduction (FFR)at IMCAS World Congress 2024, took place in Paris from February 1st - 3rd, 2024.
- 01 Nov 2023 According to a Sirnaomics media release, company announced a poster with positive clinical data of STP705 for focal fat reduction (FFR) was presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22 25 in Las Vegas.